The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. (1985)

Peer-Reviewed Study · M Dawson; P A Braithwaite; M S Roberts et al. · January 1985

M Dawson et al., 1985-01: Crossover tracer study in five volunteers finding 22% oral bioavailability of mebendazole from solution, attributed to high first-pass elimination rather than incomplete absorption.

the average time to peak plasma concentration was 0.42 h, and the bioavailability of mebendazole was 22%.

M Dawson et al., 1985-01: Crossover tracer study in five volunteers finding 22% oral bioavailability of mebendazole from solution, attributed to high first-pass elimination rather than incomplete absorption. Study type: human crossover pharmacokinetics, N=5 volunteers aged 37-64. Country: not stated in the record. Dose: tracer dose of tritiated mebendazole, intravenous and oral. Funder: not stated in the record. Declared conflicts: no COI field for this 1985 record. Comparator: intravenous versus oral dosing of the same tracer. The paper's own conclusion is that absorption at this dose level is almost complete and the low bioavailability is a first-pass effect, which is a nuance the record should keep.